Search the Newsreel

Ultra Clean Holdings: Profit On Paper, Still Burning Cash (NASDAQ:UCTT)

ATMU Q2 Deep Dive: Acquisition Integration and Market Recovery Shape Results

ATMU Q2 Deep Dive: Acquisition Integration and Market Recovery Shape Results Filtration products manufacturer Atmus Filtration Technologies (NYSE:ATMU) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 16.4% year on year to $527.9 million. Its non-GAAP profit of $0.82 per share was …

Ultragenyx to license generic DOJOLVI to Esjay starting Jan 1, 2033 under settlement

Ultragenyx announced a settlement with Esjay, resolving patent litigation concerning DOJOLVI. Under the agreement, Ultragenyx will grant Esjay a non-exclusive, royalty-free license to market a generic version of DOJOLVI beginning January 1, 2033, with a potential extension to July 1, 2033, pending pediatric exclusivity. …

Barclays Adjusts Price Target on Altria Group to $58 From $64, Keeps Underweight Rating

Barclays has lowered its price target for Altria Group (NYSE: MO) from $64 to $58, while maintaining an "Underweight" rating on the stock. This adjustment comes amidst recent news that Altria missed its quarterly profit estimates as demand for premium cigarettes weakened. The company …

Ultragenyx Pharmaceutical Inc. (RARE) Investor Outlook: Nearly 100% Upside Potential According to Analyst Ratings

Ultragenyx Pharmaceutical Inc. (RARE), focused on rare genetic diseases, shows significant upside potential, with analysts setting an average target price of $52.84, nearly double its current $26.80. Despite current negative EPS and significant R&D investments, the company's robust product pipeline, strategic collaborations, and positive …

Atmus Filtration Technologies (ATMU) Is Down 7.9% After Hiking 2026 Sales Outlook And Completing Buyback - What's Changed

Altria Group, Inc. $MO Position Increased by Charles Schwab Trust Co

Charles Schwab Trust Co significantly increased its stake in Altria Group (NYSE:MO) by 444% in the second quarter, bringing its total holdings to approximately $2.38 million. This comes as Altria reported slightly missed EPS estimates but beat revenue forecasts, maintaining its fiscal 2026 EPS …

Filtronic's (LON:FTC) Problems Go Beyond Weak Profit

Atmus Filtration Technologies (ATMU) Stock Sinks As Strong Q2 Growth Meets Cost Pressure

Atmus Filtration Technologies (ATMU) saw its stock drop by approximately 6% despite reporting strong Q2 2026 results with revenue up 16% to US$527.9m and adjusted EPS up 8%. While the company demonstrated robust profitability with an adjusted EBITDA margin of 20.7%, concerns about continued …

ETFs Investing in Atmus Filtration Technologies, Inc. Stocks

This article lists various ETFs that include Atmus Filtration Technologies, Inc. (ATMU) stocks in their holdings. The ETFs are sorted by market value and provide details such as issuer, management style, expense ratio, assets under management (AUM), and price performance. This resource aims to …

Altria Group Inc Stock (MO) Moved Down by 3.99% on Aug 10: What Signal Does It Send?

Altria Group Inc (MO) stock fell by 3.99% due to heightened regulatory uncertainty from potential FDA nicotine caps, increased competitive pressure in smoke-free segments, and macroeconomic factors like rising Treasury yields and persistent inflation. These issues are challenging Altria's core revenue, its transition to …

Ultrapar Participacoes SA expected to post earnings of 21 cents a share - Earnings Preview

Ultrapar Participacoes SA is projected to report earnings of 21 cents per share. This information is part of an earnings preview. The full article provides more details on this financial expectation.

Ultralife (ULBI) Stock Rallies On Profit Rebound As One Off Boosts Linger

Ultralife (ULBI) stock rallied 19% after reporting a return to profit in Q2 2026, with net income of US$2.5m and EPS of US$0.15. While the company saw improved profitability from its existing revenue base and growing backlog in Communications Systems, some growth was attributed …

Altria Group Inc. stock underperforms Monday when compared to competitors

Shares of Altria Group Inc. (MO) fell 4.11% on Monday, underperforming the broader market, as both the S&P 500 Index and Dow Jones Industrial Average also saw declines. The stock closed 14.95% below its 52-week high reached in late July.

Altria Group, Inc. (MO) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Altria Group, Inc. (MO) stock, including its current price, historical data, and recent news headlines. It highlights Altria's performance, particularly its focus on smoke-free products and Q2 earnings, while also noting investigations and market reactions …

ATMU or RACE: Which Is the Better Value Stock Right Now?

Investors interested in Automotive - Original Equipment stocks are likely familiar with Atmus Filtration Technologies (ATMU) and Ferrari (RACE). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. Everyone …

Can Altria's Smoke-Free Push Finally Drive Long-Term Growth?

Altria Group, Inc.'s MO smoke-free strategy is increasingly centered on nicotine pouches, with on! PLUS emerging as a key part of that effort. In the second quarter of 2026, Helix expanded on! PLUS to about 120,000 stores, covering roughly 90% of nicotine product volume. …

Ultra Clean Announces Participation at Upcoming Investor Conferences

Ultra Clean Holdings, Inc. (UCTT) announced its participation in two upcoming investor conferences: the Oppenheimer 29th Annual Technology, Internet & Communications Conference on August 11, 2026, and the 7th Annual Needham Virtual Semiconductor & SemiCap 1x1 Conference on August 19, 2026. At the Needham …

Ultragenyx Pharmaceutical's (RARE) Buy Rating Reiterated at HC Wainwright

HC Wainwright has reiterated its "buy" rating for Ultragenyx Pharmaceutical (RARE) with a $50 price target, suggesting a 93% upside from its current stock price. This aligns with a "Moderate Buy" consensus among analysts, who project an average target of $57.82. The biopharmaceutical company …

Ultra Clean Holdings (UCTT) Could Be 36% Undervalued On Second Quarter Earnings

Ultrapar Participacoes S.A. (NYSE:UGP) Given Average Recommendation of "Moderate Buy" by Analysts

Seven analysts have issued a "Moderate Buy" consensus rating for Ultrapar Participacoes S.A. (NYSE:UGP), with an average 12-month price target of $6.32. Recent upgrades include Bank of America to "buy" with a $7.40 target, and Wall Street Zen to "strong-buy." Major institutional investors, such …

How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) Q2 Revenue Gain And Narrower Net Loss

Ultragenyx Pharmaceutical (RARE) reported a Q2 2026 revenue gain of US$214 million, up from US$167 million year-over-year, and a narrower net loss of US$92 million compared to US$115 million. While these results support the investment case for its rare disease and gene therapy portfolio, …

Siltronic gibt Prognose für das Geschäftsjahr 2026 bekannt

Is Altria Group (MO) Cheap Following Mixed Q2 Earnings And Tighter 2026 Guidance?

Altria Group (MO) recently reported mixed Q2 2026 earnings, with a revenue beat but an earnings miss, leading to a tighter full-year adjusted EPS outlook. Despite a 19.26% year-to-date share price return, the stock trades at a discount to one estimate of its intrinsic …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Altria Group, Inc. (MO) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Altria Group, Inc. (MO) purchasers following the company's Q2 2026 financial results which missed Wall Street expectations and led to a lowered full-year earnings outlook. The investigation focuses on whether Altria adequately …

Is Q2 Revenue Growth And Narrower Loss Altering The Investment Case For Ultragenyx Pharmaceutical (RARE)?

On August 4, 2026, Ultragenyx Pharmaceutical Inc. reported second-quarter revenue of US$214 million versus US$167 million a year earlier, while quarterly net loss narrowed to US$92 million from US$115 million and basic loss per share from continuing operations improved to US$0.90 from US$1.17. Despite …

Balady Poultry Logs Rise in H1 Net Profit; Revenue Declines

Ultra Clean (NASDAQ:UCTT) Stock Rating Upgraded by Wall Street Zen

Is Record Q2 Results And Raised Outlook Altering The Investment Case For Atmus Filtration Technologies (ATMU)?

Atmus Filtration Technologies Inc. reported past second-quarter 2026 results with record sales of US$527.9 million and net income of US$63.9 million, and raised its full-year 2026 net sales guidance to a range of US$1.98 billion to US$2.03 billion. The quarter highlighted the contribution from …

Has Ultragenyx Pharmaceutical (RARE) Fallen Far Enough To Avoid Overvaluation?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Ultragenyx Pharmaceutical stock is coming off a difficult longer term stretch, with the share price down about 72.1% over five years. Current valuation checks …

Altria’s Dividend Still Yields 6.5%, But Can Earnings Keep Up?

Ultragenyx Pharmaceutical (RARE) Following Q2 Results Looks Close To Fair Value

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Ultragenyx Pharmaceutical (RARE) released its second quarter 2026 results on 4 August, reporting revenue of US$214 million and a net loss of US$92 million. …

MO Investors Have Opportunity to Join Altria Group, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Altria Group, Inc. (NYSE: MO) following the company's Q2 2026 financial results and a cut to its full-year outlook, which caused share prices to fall. The firm is looking into whether Altria issued …

Ultralife reports Q2 revenue $47.9M, GAAP EPS $0.15 and adjusted EBITDA $6.1M

Ultralife (ULBI) announced its Q2 2026 financial results, reporting revenues of $47.9 million, GAAP EPS of $0.15, and adjusted EBITDA of $6.1 million. The company achieved a record backlog of $117.5 million and improved its gross profit margin to 28.9%. Strategic initiatives included new …

Ultralife (NASDAQ:ULBI) Posts Earnings Results, Hits Expectations

Ultralife (NASDAQ:ULBI) announced its quarterly earnings, meeting EPS expectations at $0.19 but missing revenue estimates with $47.94 million against a $55 million consensus. Despite a year-over-year revenue decline, the company saw improved profitability, with GAAP EPS rising to $0.15 and gross margin expanding to …

Atmus Filtration Technologies Inc. Q2 2026: Revenue $527.9M, EPS $0.78— 10-Q Summary

Atmus Filtration Technologies Inc. reported strong Q2 2026 results, with revenue reaching $527.9 million and diluted EPS at $0.78, marking a significant increase from the previous year. The company attributed this growth to expanding digital channels, pricing improvements, and higher service adoption. Additionally, Atmus …